Just 3 days ago, Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, www.pvct.com), signed an agreement with Numoda Capital Innovations LLC (www.numodacapital.com) to license its TruPoints® strategic partnering platform. Provectus plans to make PH-10, a therapy treatment of serious dermatological diseases, which recently showed positive Phase 2 clinical trial results in both Atopic Dermatitis and Psoriasis. In pursuit of this development, the company will use Numoda’s TruPoints to facilitate transactions with potential licensing partners for PH-10 and it will organize all due diligence material relating to the Phase 2 clinical trials.
The desired outcome of the agreement is to improve the flow of information to potential licensees. Numoda’s TruPoints platform already has an excellent reputation for helping numerous development stage biotech companies secure big pharma licensing agreements. Craig Dees, Ph.D., CEO of Provectus said, “As we actively seek to out-license PH-10, Numoda TruPoints will enable the exchange of scientific and business information between Provectus and potential partners. We expect this platform to play a critical role in the out-licensing process when we formally engage an investment banker.” As for today, the Provectus-Numoda deal is already creating some buzz and showing consumer confidence with it's margins up by over 3% since the previous close.
for more information.